Molecular Mechanisms of Neuroinflammation in ME/CFS and Long COVID to Sustain Disease and Promote Relapses.
Tate, Warren, Walker, Max, Sweetman, Eiren et al. · Frontiers in neurology · 2022 · DOI
Quick Summary
This study explores why ME/CFS and Long COVID symptoms persist and come and go in cycles. The researchers propose that after an initial trigger—like a viral infection, chemical exposure, or major stress—inflammation spreads to the brain through damaged blood vessels, causing ongoing brain inflammation that keeps the illness cycling. They suggest that similar mechanisms may explain why both ME/CFS (from various causes) and Long COVID (from COVID-19) produce remarkably similar symptoms despite different starting triggers.
Why It Matters
This study matters because it offers a coherent theoretical framework explaining why ME/CFS symptoms are persistent and cyclical despite diverse initial causes, and why Long COVID so closely mirrors ME/CFS despite arising from a single pathogen. Understanding these shared neuroinflammatory mechanisms could guide future research toward targeted biomarkers and treatments that address the brain's role in sustaining disease. For patients, this hypothesis emphasizes that neurological dysfunction is central to the illness rather than peripheral or psychiatric.
Observed Findings
ME/CFS arises from diverse triggers (viral infection, chemical exposure, surgery, severe stress) yet produces remarkably similar symptom profiles and relapse-recovery cycles.
Both ME/CFS and Long COVID feature brain-centered symptoms including neuroinflammation, cognitive dysfunction ('brain fog'), sleep disturbance, and poor stress tolerance.
Systemic molecular inflammatory responses and chronic immune dysregulation are documented in ME/CFS, but the mechanisms linking peripheral inflammation to brain pathology remain unclear.
The hierarchy of physiological responses that generate specific symptoms in ME/CFS and why they persist without resolution are poorly established.
Inferred Conclusions
Chronic neuroinflammation sustained via neurovascular dysfunction and blood-brain barrier compromise may be a common pathogenic mechanism across ME/CFS (regardless of trigger) and Long COVID.
Bidirectional signaling between the brain and peripheral immune/physiological systems likely perpetuates disease cycles and prevents healing.
The similarity of symptoms across ME/CFS and Long COVID despite different initial stressors suggests a shared dysfunction in central nervous system homeostasis rather than pathogen-specific mechanisms.
Remaining Questions
What are the specific molecular pathways and timeline by which peripheral inflammation breaches the blood-brain barrier and initiates chronic CNS inflammation?
What This Study Does Not Prove
This study does not prove that blood-brain barrier dysfunction or neuroinflammation actually occurs in ME/CFS patients—it proposes a hypothesis based on existing literature rather than presenting new experimental data. It does not establish causation or identify which mechanisms are primary versus secondary, nor does it explain why some patients recover while others develop chronic illness. The study also does not distinguish between distinct biological subtypes of ME/CFS or validate that Long COVID and ME/CFS share identical pathogenic mechanisms.
What mechanisms determine why some individuals develop chronic ME/CFS after a triggering event while others recover, and are there distinct biological subtypes?
How do bidirectional brain-to-body signaling pathways sustain peripheral immune dysregulation, and which specific pathways are therapeutic targets?
Do ME/CFS and Long COVID truly share identical neuroinflammatory mechanisms, or are there pathogen-specific or trigger-specific variations that require different treatment approaches?